What is OnKure Therapeutics, Inc. (OKUR) stock price today?

OnKure Therapeutics, Inc. (OKUR) currently trades at $3.44 per share. The stock has a market capitalization of $157.95M and a P/E ratio of —x.

Is OKUR stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, OnKure Therapeutics, Inc. has a Smart Value Score of 30/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 4/9 and Altman Z-Score is 3.00.

Is OnKure Therapeutics, Inc. financially healthy?

OnKure Therapeutics, Inc.'s Piotroski F-Score is 4/9 (moderate financial health). The Altman Z-Score of 3.00 places it in the safe zone.

OKUR

OnKure Therapeutics, Inc.

NASDAQ: OKUR · HEALTHCARE · BIOTECHNOLOGY

$3.44

-12.02% today

Updated 2026-05-11

Market cap

$157.95M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-4.32

Dividend yield

—

52W range

$2 – $5

Volume

0.3M

Market cap

$157.95M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-4.32

Dividend yield

—

52W range

$2 – $5

Volume

0.3M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

9.0

Quality

A+

3.0

Profitability

5.0

Valuation

C+

4/9

Piotroski F-Score

Moderate

3.0

Altman Z-Score

Safe zone

—

Industry rank

—

View all highly rated stocks (75+) →198 stocks currently score above 75

Price targets

Analyst target

$20.20

+487.21%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Altman Z 3.00 — safe zone

+ Debt/equity 0.01x — low leverage

Risks

- Thin margins at 0.00%

- Negative free cash flow $-12.94M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	—
Net income	$-29.51M	$-35.31M	$-52.67M	$-59.52M	$-15.16M
EPS	—	—	—	—	$-4.32
Free cash flow	$-28.09M	$-34.79M	$-51.17M	$-51.87M	$-12.94M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
OKUR	$157.95M	30	4.3	3.0	5.0	9.0	—	Avoid
LLY	$869.41B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$535.63B	59	4.7	9.0	3.3	6.0	-37.47%	Buy
ABBV	$358.55B	63	4.0	8.0	4.0	5.0	-19.74%	Buy
UNH	$335.78B	54	5.3	5.5	7.3	4.8	+40.60%	Buy
AZN	$283.47B	62	6.0	8.5	5.3	5.0	+6.51%	Buy

Smart narrative

OnKure Therapeutics, Inc. trades at $3.44. Our Smart Value Score of 30/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 3.00, it sits in the safe zone.

Frequently asked questions

What is OnKure Therapeutics, Inc.'s stock price?

OnKure Therapeutics, Inc. (OKUR) trades at $3.44.

Is OnKure Therapeutics, Inc. overvalued?

Smart Value Score 30/100 (Grade F, Strong Sell).

What is the price target of OnKure Therapeutics, Inc. (OKUR)?

The analyst target price is $20.20, representing +487.2% upside from the current price of $3.44.

Piotroski F-Score?

4/9 — moderate financial health.

Altman Z-Score?

3.00 — safe zone.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

onkuretherapeutics.com

Quick metrics

P/S ratio—

ROE-42.70%

Beta—

50D MA$4.18

200D MA$3.12

Shares out0.04B

Float0.02B

Short ratio—

Avg volume0.3M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

OKUR vs LLY →OKUR vs JNJ →OKUR vs ABBV →Stock screener →